Palvella Therapeutics (PVLA) Projected to Post Earnings on Thursday

Palvella Therapeutics (NASDAQ:PVLA) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 15th. Analysts expect Palvella Therapeutics to post earnings of ($3.40) per share for the quarter.

Palvella Therapeutics Stock Down 8.9%

Palvella Therapeutics stock opened at $20.75 on Tuesday. The business has a 50 day moving average price of $24.87. The stock has a market cap of $229.14 million, a price-to-earnings ratio of -1.71 and a beta of 0.10. Palvella Therapeutics has a 12-month low of $6.20 and a 12-month high of $29.27.

Insider Activity

In related news, Director George M. Jenkins bought 2,500 shares of the business’s stock in a transaction on Wednesday, April 9th. The shares were bought at an average price of $20.13 per share, for a total transaction of $50,325.00. Following the completion of the purchase, the director now directly owns 183,171 shares of the company’s stock, valued at approximately $3,687,232.23. This trade represents a 1.38% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 6.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on PVLA. HC Wainwright reissued a “buy” rating and issued a $38.00 target price on shares of Palvella Therapeutics in a report on Wednesday, April 30th. Scotiabank assumed coverage on Palvella Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 target price for the company. TD Cowen assumed coverage on Palvella Therapeutics in a research report on Wednesday, February 5th. They issued a “buy” rating and a $44.00 price target for the company. Jones Trading started coverage on Palvella Therapeutics in a research report on Tuesday, March 25th. They issued a “buy” rating and a $45.00 price target for the company. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $39.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Palvella Therapeutics currently has an average rating of “Buy” and an average price target of $44.43.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.